Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00006474 · ClinicalTrials.gov registry record · Phase 1

Temozolomide and O6-benzylguanine in Treating Patients With Newly Diagnosed, Recurrent, or Progressive Anaplastic Glioma

A Phase 1 study, sponsored by Duke University.

Completed
Registry status
Phase 1
Development phase

NCT00006474: Completed Phase 1 study, sponsored by Duke University.

NCT00006474 is a Phase 1 study that has completed, run by Duke University. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00006474, a Phase 1 study, has completed, sponsored by Duke University.

COMPLETED
Registry status
Phase 1
Development phase

Study Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of combining temozolomide and O6-benzylguanine in treating patients who have newly diagnosed, recurrent, or progressive anaplastic glioma.

Interventions

  • DRUG O6-benzylguanine
  • DRUG temozolomide
  • PROCEDURE conventional surgery

Trial Details

FieldValue
Start Date 2001-03
Est. Completion 2004-08
Phase Phase 1
Duke University

1,725 total trials

What the finished NCT00006474 record still lists

NCT00006474 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.

The record links to 0 conditions, and to 3 interventions - of which O6-benzylguanine is the first listed.

NCT00006474 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00006474 about?

NCT00006474 is a clinical study titled "Temozolomide and O6-benzylguanine in Treating Patients With Newly Diagnosed, Recurrent, or Progressive Anaplastic Glioma". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of combining temozolomide and O6-benzylguanine in treating patients who h...

What is the current status of trial NCT00006474?

This trial is currently completed. It is a Phase 1 study. The study started on 2001-03. Estimated completion is 2004-08.

What interventions are being tested in trial NCT00006474?

The interventions under investigation include: O6-benzylguanine (DRUG), temozolomide (DRUG), conventional surgery (PROCEDURE).

Who is sponsoring clinical trial NCT00006474?

This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00006474, the US trial registry maintained by the National Library of Medicine. NCT00006474 (unsized enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.